What is the KESETT Study?
KESETT (Ketamine Add-On Therapy for Established Status Epilepticus Treatment Trial) is a proposed three-armed, Bayesian adaptive randomized trial comparing two doses of ketamine plus levetiracetam versus levetiracetam alone for treating benzodiazepine-refractory status epilepticus 1.
Study Design and Rationale
The KESETT trial represents a novel approach to addressing treatment gaps identified in the landmark ESETT (Established Status Epilepticus Treatment Trial) study. While ESETT demonstrated that levetiracetam, fosphenytoin, and valproate all achieve seizure cessation in approximately 47% of benzodiazepine-refractory status epilepticus cases 2, this leaves roughly half of patients without adequate seizure control.
The KESETT trial specifically targets this treatment gap by investigating ketamine as an add-on therapy, based on the mechanistic rationale that prolonged seizures cause GABA receptor internalization, making benzodiazepines less effective while NMDA antagonists like ketamine may restore responsiveness 3.
Key Study Features
Primary Outcome
The trial employs an ordinal primary outcome at 60 minutes ranging from:
- 1 = improving consciousness and seizure cessation (best outcome)
- 5 = life-threatening event/death (worst outcome)
This ordinal scale is expected to show a bimodal distribution based on previous status epilepticus studies 1.
Treatment Arms
- Arm 1: Levetiracetam alone (control)
- Arm 2: Ketamine (lower dose) + levetiracetam
- Arm 3: Ketamine (higher dose) + levetiracetam
Methodological Innovation
The trial uses a Bayesian adaptive design with an "expected score approach" to analyze the ordinal outcome data. This methodology was specifically developed because traditional proportional odds assumptions are inappropriate for the expected bimodal distribution of status epilepticus outcomes 1.
Clinical Context and Supporting Evidence
Why Ketamine for Status Epilepticus?
Current 2024 ACEP guidelines identify ketamine as a prospective area of research for status epilepticus treatment 2. Recent evidence supports this direction:
- Systematic review data: Ketamine achieves a pooled seizure cessation rate of 64% (95% CI 49%-76%) in refractory/super-refractory status epilepticus 4
- Timing matters: Earlier ketamine administration (within 3.2 days vs 4.3 days) correlates with better outcomes, with a mean difference of -0.90 days (p < 0.0001) 4
- Safety profile: Ketamine discontinuation due to adverse events is rare (0.7%, 3/55 patients) 4
The "Stage 1 Plus" Concept
KESETT addresses what some experts term "Stage 1 Plus" status epilepticus—cases with features predicting benzodiazepine resistance:
- Prolonged SE (>10 minutes)
- Absence of prominent motor phenomena
- Acute CNS etiology
These cases may benefit from early NMDA antagonist therapy like ketamine rather than waiting for benzodiazepine failure 3.
Practical Implications
Dosing Considerations from Related Research
While KESETT's exact dosing remains to be published, related research indicates:
- Maintenance doses below 0.9 mg/kg/hr are ineffective for SE termination 3
- Typical maintenance dosing in refractory SE: 2.5 ± 1.4 mg/kg/hr 4
- Average infusion duration: 5.0 ± 4.2 days 4
Pediatric Pharmacokinetic Support
Machine learning models using population pharmacokinetics have been developed to predict early ketamine exposure in pediatric status epilepticus, addressing the challenge of limited sampling in emergency settings 5. This supports the feasibility of ketamine use across age groups in SE.
Important Caveats
The KESETT trial is still in the proposal/design phase 1. Current ketamine use in status epilepticus remains off-label, though increasingly supported by observational data and systematic reviews 4, 3. The FDA-approved indications for ketamine are limited to anesthesia and procedural sedation 6, not status epilepticus treatment.
The trial's completion will provide crucial Class I evidence to guide whether ketamine should be incorporated into standard status epilepticus treatment algorithms, potentially as early as second-line therapy rather than waiting for refractory or super-refractory stages.